CN115969830A - 保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 - Google Patents
保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 Download PDFInfo
- Publication number
- CN115969830A CN115969830A CN202310194076.1A CN202310194076A CN115969830A CN 115969830 A CN115969830 A CN 115969830A CN 202310194076 A CN202310194076 A CN 202310194076A CN 115969830 A CN115969830 A CN 115969830A
- Authority
- CN
- China
- Prior art keywords
- hypertension
- relieving
- complications
- medicine
- protectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 65
- 239000003814 drug Substances 0.000 title claims abstract description 23
- CRDZYJSQHCXHEG-SFVBTVKNSA-N protectin D1 Chemical compound CC\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-SFVBTVKNSA-N 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title description 4
- 230000001681 protective effect Effects 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000001631 hypertensive effect Effects 0.000 claims description 6
- 208000007530 Essential hypertension Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 3
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 3
- 201000004239 Secondary hypertension Diseases 0.000 claims description 3
- 201000009939 hypertensive encephalopathy Diseases 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 3
- 230000035488 systolic blood pressure Effects 0.000 abstract description 20
- 230000035487 diastolic blood pressure Effects 0.000 abstract description 19
- 208000032594 Vascular Remodeling Diseases 0.000 abstract description 11
- 230000036772 blood pressure Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000002547 new drug Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 102000005862 Angiotensin II Human genes 0.000 description 14
- 101800000733 Angiotensin-2 Proteins 0.000 description 14
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 14
- 229950006323 angiotensin ii Drugs 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000012188 paraffin wax Substances 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 238000009530 blood pressure measurement Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000008096 xylene Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 210000000702 aorta abdominal Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 241000581650 Ivesia Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 241000209639 Biancaea sappan Species 0.000 description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000006906 Vascular Ring Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了保护素D1在制备缓解和/或治疗高血压病及其并发症药物中的应用,属于医药技术领域。本发明发现保护素D1能够降低高血压模型收缩压和舒张压,减轻高血压血管重构,其可作为活性成分用于制备缓解和/或治疗高血压病及其相关并发症的药物。本发明发现了保护素D1降低血压和减轻高血压血管重构的新功能,为研制缓解和/或治疗高血压并及其并发症的新药物提供了靶标。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种小分子物质保护素D1在制备缓解和/或治疗高血压病及其并发症药物中的应用。
背景技术
高血压病作为一种普遍的慢性疾病,其逐年上升的患病率与死亡率,一直受到中外医学界的高度重视[1]。据统计,2015年中国18岁以上人群中已有2.45亿的高血压患者[2],2017年中国有254万人死于收缩压升高,伤残调整寿命年超过5%[3]。我国的高血压知晓率和治疗率分别为51.6%和45.8%,而总体控制率仍然很低,仅为16.8%,仍处于较低水平[4]。鉴于高血压具有极高的患病率和较低的知晓率、治疗率及控制率,因此寻找更加安全、更加有效的预防和治疗高血压策略和药物具有重要意义[5]。
保护素D1(Protectin D1,PD1)属于特异性促炎症消退脂质介质,是一种具有抗炎和促炎症消退作用的内源性小分子物质[6]。在抗炎方面,PD1能够减轻脓毒症炎症反应[7];在炎症消退方面,PD1可增强巨噬细胞的吞噬能力,促进炎症消退和疼痛缓解[8]。然而,PD1在高血压病中的作用仍然未知。
参考文献:
1.马丽媛,王增武,樊静,胡盛寿.《中国心血管健康与疾病报告2021》关于中国高血压流行和防治现状[J].中国全科医学,2022,25(30):3715-3720.
2.WANG Z W,CHEN Z,ZHANG L F,et al.Status of hypertension in China:results from the China hypertension survey,2012-2015[J].Circulation,2018,137(22):2344-2356.DOI:10.1161/CIRCULATIONAHA.117.032380.
3.GBD 2017DALYs and HALE Collaborators.Global,regional,and nationaldisability-adjusted life-years(DALYs)for 359diseases and injuries and healthylife expectancy(HALE)for 195countries and territories,1990-2017:a systematicanalysis for the Global Burden of Disease Study2017[J].Lancet,2018,392(10159):1859-1922.DOI:10.1016/S0140-6736(18)32335-3
4.郭艺芳.我国高血压防控现状的最新数据与启示[J].中华高血压杂志,2016,24(06):504.DOI:10.16439/j.cnki.1673-7245.2016.06.003.
5.王增武.中国高血压流行和防治现状[J].中国心血管病研究,2022,20(08):673-678.
6.Vartak T,Godson C,Brennan E.Therapeutic potential of pro-resolvingmediators in diabetic kidney disease.Adv Drug Deliv Rev 2021,178:113965.
7.Bang S,Donnelly CR,Luo X,Toro-Moreno M,Tao X,Wang Z,Chandra S,Bortsov AV,Derbyshire ER,Ji RR.Activation of GPR37 in macrophages confersprotection against infection-induced sepsis and pain-like behaviour inmice.Nat Commun 2021,12(1):1704.
8.Bang S,Xie YK,Zhang ZJ,Wang Z,Xu ZZ,Ji RR.GPR37 regulatesmacrophage phagocytosis and resolution of inflammatory pain.J Clin Invest2018,128(8):3568-3582.
发明内容
目前现代医学关于高血压的治疗方案仍存在不足,因此需要新颖的治疗手段/药物提高高血压控制率,预防高血压并发症,改善高血压患者预后。本发明发现了保护素D1能够降低高血压模型收缩压和舒张压,减轻高血压血管重构。本发明的目的在于提供一种保护素D1在制备缓解和/或治疗高血压病及其并发症药物中的新应用。
本发明的目的通过下述技术方案实现:
本发明以C57BL/6小鼠为实验对象,给予保护素D1(2μg/kg/d,以生理盐水为溶剂,腹腔注射),使用微量渗透泵皮下泵注血管紧张素Ⅱ(750ng/kg/分钟)构建小鼠高血压模型,观察保护素D1对小鼠高血压模型血压及血管重构的作用。结果表明,保护素D1可显著降低高血压小鼠的收缩压和舒张压,并减轻血管重构。本发明为研究缓解和/或治疗高血压及其并发症的新策略提供了理论依据和临床基础。
本发明提供了保护素D1在制备缓解和/或治疗高血压病及其相关并发症药物中的应用。所述的应用中,以保护素D1为活性成分制备缓解和/或治疗高血压病及其相关并发症的药物。
本发明还提供了一种缓解和/或治疗高血压病及其相关并发症的药物。所述的药物包含保护素D1,还可包含保护素D1药学上可接受的载体。
所述的高血压病及其相关并发症包括但不限于:原发性高血压,继发性高血压,高血压性心脏病,高血压心力衰竭,高血压性脑病,高血压视网膜病变,高血压肾病。
本发明的优点和有益效果:
(1)本发明发现了保护素D1的新功能,即保护素D1具有降低血压,减轻高血压血管重构的作用。
(2)基于保护素D1降低血压和减轻高血压血管重构的功能,为研制缓解和/或治疗高血压并及其并发症的新药物提供了靶标。
(3)以保护素D1有效成分,可用于制备缓解和/或治疗高血压并及其并发症的新药物。
附图说明
图1是保护素D1降低小鼠高血压模型中收缩压和舒张压的结果图。图中,AngⅡ:血管紧张素Ⅱ;Control:对照组;PD1:保护素D1。**表示p<0.01差异有统计学意义。
图2是保护素D1减轻小鼠高血压血管重构的结果图。A:小鼠腹主动脉苏木精—伊红(HE)染色及主动脉中膜厚度统计结果;B:小鼠腹主动脉天狼猩红(PSR)染色及纤维化程度统计结果。AngⅡ:血管紧张素Ⅱ;Control:对照组;PD1:保护素D1。**表示p<0.01,***表示p<0.001,****表示p<0.0001,差异有统计学意义。
图3是巨噬素1对小鼠高血压模型中收缩压和舒张压无影响的结果图。图中,AngⅡ:血管紧张素Ⅱ;Control:对照组;MaR1:巨噬素1。无统计学意义。
图4是巨噬素2对小鼠高血压模型中收缩压和舒张压无影响的结果图。图中,AngⅡ:血管紧张素Ⅱ;Control:对照组;MaR2:巨噬素2。无统计学意义。
具体实施方式
以下实施例用于进一步说明本发明,但不应理解为对本发明的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
实验动物及饲养:C57BL/6小鼠,雄性,8周龄,购自江苏集萃药康生物科技股份有限公司。饲养在武汉大学人民医院标准化实验动物中心(SPF级),饲养条件:温度在22-24℃之间,湿度在40-70%之间,明暗交替照明时间为12h,自由饮水摄食。
实施例1保护素D1降低小鼠收缩压和舒张压
1.小鼠高血压模型
(1)小鼠在SPF级标准化动物中心适应环境1周。
(2)将血管血管紧张素Ⅱ溶液(溶剂为生理盐水)装入微量渗透泵(MODEL 2004,美国alzet公司),37℃恒温激活渗透泵≥40小时,然后将微量渗透泵置入小鼠背部皮下,持续泵注血管紧张素Ⅱ(750ng/kg/分钟)28天,从而构建小鼠高血压模型。
2.保护素D1给药方式
血管紧张素Ⅱ泵注第一天开始,通过腹腔注射给予PD1,剂量为2μg/kg,每天一次,连续给药28天,溶剂为生理盐水,对照组同时给予等量安慰剂(生理盐水)。
3.小鼠尾动脉血压测量
分别于高血压模型前和实验开始第1周、2周、3周、4周,使用小鼠无创血压测量仪(CODA,美国KENT公司)测量小鼠尾动脉血压(收缩压和舒张压)。血压测量统一在8:00-12:00进行,每次测量执行15个循环(其中前5个循环为适应性测量,测量数据不纳入),取平均值为小鼠血压(收缩压和舒张压)。此外,实验前,对小鼠进行血压测量适应训练3-5次。
小鼠收缩压和舒张压结果如图1所示:保护素D1显著降低小鼠高血压模型中收缩压和舒张压。
实施例2保护素D1减轻高血压血管重构
1.腹主动脉血管中膜厚度测定
(1)制备石蜡标本及切片
1)高血压模型4周后,安乐死小鼠,剥离小鼠完整主动脉,取腹主动脉置于10%福尔马林溶液中固定。72小时后,将主动脉组织从10%福尔马林溶液取出,在通风橱内修剪组织,并将修剪好的主动脉组织和相对应的标签置于脱水盒中。
2)脱水浸蜡:将脱水盒放进脱水机中,进行脱水浸蜡处理。75%乙醇(4h)→85%乙醇(2h)→90%乙醇(2h)→95%乙醇(1h)→无水乙醇I(30min)→无水乙醇II(30min)→醇苯(5-10min)→二甲苯I(5-10min)→二甲苯II(5-10min)→65℃融化石蜡I(1h)→65℃融化石蜡II(1h)→65℃融化石蜡III(1h)。
3)组织包埋:先将融化的石蜡注入进包埋框中,趁石蜡未凝固时,从脱水盒内将主动脉组织取出,血管环横切面朝下放入包埋框中,并贴上相对应的标签,水平置于-20℃冻台上冷却。待石蜡凝固后,从包埋框中将蜡块取出。
4)组织切片:将蜡块进行修整并固定在石蜡切片机上,切片厚度为4-5μm。转动切片机手柄连续切片,使切片漂浮于温水中并将切片展平。用载玻片将切片捞起,使切片位于载玻片的正中位置,置于60℃烘箱内烘烤,保存备用。
(2)腹主动脉苏木精—伊红染色(HE)
使用上述石蜡切片,依次进行以下操作:
1)二甲苯(Ⅰ)15min;
2)二甲苯(Ⅱ)15min;
3)甲苯:无水乙醇=1:12min;
4)100%乙醇(Ⅰ)5min;
5)100%乙醇(Ⅱ)5min;
6)80%乙醇5min;
7)蒸馏水5min;
8)苏木精液染色5min;
9)流水稍洗去苏木精液1-3s;
10)1%盐酸乙醇1-3s;
11)水洗10-30s;
12)蒸馏水过洗1-2s;
13)0.5%伊红液染色1-3min;
14)蒸馏水稍洗1-2s;
15)80%乙醇稍洗1-2s;
16)95%乙醇(Ⅰ)2-3s;
17)95%乙醇(Ⅱ)3-5s;
18)无水乙醇(I)5-10min;
19)无水乙醇(II)5-10min;
20)二甲苯(Ⅰ)2min;
21)二甲苯(Ⅱ)2min;
22)二甲苯(Ⅲ)2min;
23)中性树胶封固;
待玻片晾干后,使用光学显微镜拍照记录,并用Image-J计算主动脉中膜厚度。
2.腹主动脉纤维化测定
(1)腹主动脉天狼猩红(PSR)染色
1)将上述石蜡切片置于二甲苯溶液中5min,同样重复3次。
2)相继经过100%、90%、70%的乙醇1次1min。
3)用流水冲洗标本10min。
4)冲洗完毕将标本置入纯水中清洗1min,再置于0.2%磷钼酸中1-5min。
5)将切片摆放于潮湿的染色盒中,滴入数滴0.1%天狼猩红苦味酸溶液使其充分与标本接触,染色90min。
6)充分甩去天狼猩红苦味酸溶液,再浸入纯水中数次。
7)最后经过70%、95%乙醇各30秒,100%乙醇30秒3次。
8)二甲苯2min重复3次,封片。
9)染色后切片用光学显微镜拍照记录,并用Image-Pro Plus进行计算主动脉纤维化程度。
主动脉中膜厚度和纤维化程度结果如图2所示,在小鼠高血压模型中,保护素D1明显减轻主动脉中膜厚度,减轻主动脉纤维化程度,表明保护素D1明显减轻高血压血管重构。
实施例3巨噬素1对小鼠收缩压和舒张压无影响
1.小鼠高血压模型
(1)小鼠在SPF级标准化动物中心适应环境1周。
(2)将血管血管紧张素Ⅱ溶液(溶剂为生理盐水)装入微量渗透泵(MODEL 2004,美国alzet公司),37℃恒温激活渗透泵≥40小时,然后将微量渗透泵置入小鼠背部皮下,持续泵注血管紧张素Ⅱ(750ng/kg/分钟)28天,从而构建小鼠高血压模型。
2.巨噬素1给药方式
血管紧张素Ⅱ泵注第一天开始,通过腹腔注射给予巨噬素1(MaR1),剂量为2μg/kg,每天一次,连续给药28天,溶剂为生理盐水,对照组同时给予等量安慰剂(生理盐水)。
3.小鼠尾动脉血压测量
分别于高血压模型前和实验开始第1周、2周、3周、4周,使用小鼠无创血压测量仪(CODA,美国KENT公司)测量小鼠尾动脉血压(收缩压和舒张压)。血压测量统一在8:00-12:00进行,每次测量执行15个循环(其中前5个循环为适应性测量,测量数据不纳入),取平均值为小鼠血压(收缩压和舒张压)。此外,实验前,对小鼠进行血压测量适应训练3-5次。
小鼠收缩压和舒张压结果如图1所示:巨噬素1显著降低小鼠高血压模型中收缩压和舒张压。
实施例4巨噬素2对小鼠收缩压和舒张压无影响
1.小鼠高血压模型
(1)小鼠在SPF级标准化动物中心适应环境1周。
(2)将血管血管紧张素Ⅱ溶液(溶剂为生理盐水)装入微量渗透泵(MODEL 2004,美国alzet公司),37℃恒温激活渗透泵≥6小时,然后将微量渗透泵置入小鼠背部皮下,持续泵注血管紧张素Ⅱ(1440ng/kg/分钟)14天,从而构建小鼠高血压模型。
2.巨噬素2给药方式
血管紧张素Ⅱ泵注第一天开始,通过腹腔注射给予巨噬素2(MaR2),剂量为2μg/kg,每天一次,连续给药14天,溶剂为生理盐水,对照组同时给予等量安慰剂(生理盐水)。
3.小鼠尾动脉血压测量
分别于高血压模型前和实验开始第3天、7天、14天,使用小鼠无创血压测量仪(CODA,美国KENT公司)测量小鼠尾动脉血压(收缩压和舒张压)。血压测量统一在8:00-12:00进行,每次测量执行15个循环(其中前5个循环为适应性测量,测量数据不纳入),取平均值为小鼠血压(收缩压和舒张压)。此外,实验前,对小鼠进行血压测量适应训练3-5次。
小鼠收缩压和舒张压结果如图4所示:巨噬素2对小鼠高血压模型中收缩压和舒张压无改善作用。
上述结果表明,在小鼠高血压模型中,保护素D1能够明显降低血压,减轻高血压血管重构。保护素D1可以作为活性成分用于制备缓解和/或治疗高血压病及其相关并发症的药物。而同为促炎症消退脂质介质的巨噬素1、巨噬素2对收缩压和舒张压无明显改善作用。
Claims (6)
1.保护素D1在制备缓解和/或治疗高血压病及其并发症药物中的应用。
2.根据权利要求1所述的应用,其特征在于:以保护素D1为活性成分制备缓解和/或治疗高血压病及其并发症的药物。
3.根据权利要求1所述的应用,其特征在于:所述的高血压病及其并发症包括:原发性高血压,继发性高血压,高血压性心脏病,高血压心力衰竭,高血压性脑病,高血压视网膜病变,高血压肾病。
4.一种缓解和/或治疗高血压病及其并发症的药物,其特征在于:包含保护素D1。
5.根据权利要求4所述的药物,其特征在于:还包含保护素D1药学上可接受的载体。
6.根据权利要求4所述的药物,其特征在于:所述的高血压病及其并发症包括:原发性高血压,继发性高血压,高血压性心脏病,高血压心力衰竭,高血压性脑病,高血压视网膜病变,高血压肾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310194076.1A CN115969830A (zh) | 2023-02-28 | 2023-02-28 | 保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310194076.1A CN115969830A (zh) | 2023-02-28 | 2023-02-28 | 保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115969830A true CN115969830A (zh) | 2023-04-18 |
Family
ID=85976421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310194076.1A Pending CN115969830A (zh) | 2023-02-28 | 2023-02-28 | 保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115969830A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050261255A1 (en) * | 2002-08-12 | 2005-11-24 | Serhan Charles N | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
US20080279925A1 (en) * | 2007-05-10 | 2008-11-13 | Undurti Narasimha Das | Method(s) of preventing, arresting, reversing and treatment of atherosclerosis |
US20090156673A1 (en) * | 2005-10-03 | 2009-06-18 | The Brigham And Women's Hospital, Inc. Corporate Sponsored Research & Licensing | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers |
US20150352069A1 (en) * | 2013-01-25 | 2015-12-10 | Universite Laval | Use of Protectin DX for the Stimulation of Muscular IL-6 Secretion |
US20180116990A1 (en) * | 2016-10-04 | 2018-05-03 | UND Life Sciences, LLC | Composition of bioactive lipids and methods of use thereof |
CN110325185A (zh) * | 2017-01-18 | 2019-10-11 | 巴塞罗那自治大学 | 用于治疗神经退行性疾病和/或自身免疫性疾病的专门的促消退脂质介质 |
-
2023
- 2023-02-28 CN CN202310194076.1A patent/CN115969830A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050261255A1 (en) * | 2002-08-12 | 2005-11-24 | Serhan Charles N | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
US20090156673A1 (en) * | 2005-10-03 | 2009-06-18 | The Brigham And Women's Hospital, Inc. Corporate Sponsored Research & Licensing | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers |
US20080279925A1 (en) * | 2007-05-10 | 2008-11-13 | Undurti Narasimha Das | Method(s) of preventing, arresting, reversing and treatment of atherosclerosis |
US20150352069A1 (en) * | 2013-01-25 | 2015-12-10 | Universite Laval | Use of Protectin DX for the Stimulation of Muscular IL-6 Secretion |
US20180116990A1 (en) * | 2016-10-04 | 2018-05-03 | UND Life Sciences, LLC | Composition of bioactive lipids and methods of use thereof |
CN110325185A (zh) * | 2017-01-18 | 2019-10-11 | 巴塞罗那自治大学 | 用于治疗神经退行性疾病和/或自身免疫性疾病的专门的促消退脂质介质 |
Non-Patent Citations (8)
Title |
---|
CAROLINE MORIN等: "Docosahexaenoic Acid Derivative Prevents Inflammation and Hyperreactivity in Lung", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 45, 31 December 2011 (2011-12-31), pages 366 - 375 * |
CAROLINE MORIN等: "Docosahexaenoic Acid Monoacylglyceride Decreases Endothelin-1 Induced Ca2+ Sensitivity and Proliferation in Human Pulmonary Arteries", AMERICAN JOURNAL OF HYPERTENSION, vol. 25, no. 7, 31 July 2012 (2012-07-31), pages 756 - 763 * |
CAROLINE MORIN等: "Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction", AM J PHYSIOL HEART CIRC PHYSIOL, vol. 309, 24 April 2015 (2015-04-24), pages 93 * |
MERCHED等: "Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators", THE FASEB JOURNAL • RESEARCH COMMUNICATION, vol. 22, 31 October 2008 (2008-10-31), pages 3595 - 3606, XP055306717, DOI: 10.1096/fj.08-112201 * |
刘小雨等: "NF-κB 在心血管疾病中的作用", 同济大学学报( 医学版), vol. 33, no. 5, 31 October 2012 (2012-10-31), pages 120 - 124 * |
张武霞等: "特异性促炎症消退介质结构与功能研究进展", 免疫学杂志, vol. 36, no. 5, 31 May 2020 (2020-05-31), pages 432 - 441 * |
王燕等: "保护素D1对中性粒细胞和人脐静脉内皮细胞 黏附性的影响", 临床麻醉学杂志, vol. 29, no. 1, 31 January 2013 (2013-01-31), pages 65 - 68 * |
鲍华燕等: "脂氧素A4、保护素D1、ResolvinD1 抑制多种激动剂引起的NFκB 的活化", 药学实践杂志, vol. 30, no. 3, 25 May 2012 (2012-05-25), pages 186 - 188 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maggiore et al. | The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial | |
Ferrantelli et al. | The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis | |
Moss et al. | The centrineurogenic etiology of the acute respiratory distress syndromes: Universal, species—independent phenomenon | |
RU2359693C2 (ru) | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний | |
US20060198913A1 (en) | Method of improvement of blood circulation | |
CN115969830A (zh) | 保护素d1在制备缓解和/或治疗高血压病及其并发症药物中的应用 | |
Liu et al. | Trehalose ameliorates diabetic cardiomyopathy: role of the PK2/PKR pathway | |
WO2012079419A1 (zh) | 一种治疗黄斑变性的药物组合物 | |
CN108498521B (zh) | 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用 | |
CA2512147C (en) | Aqueous extract of red vine leave and use thereof for improving blood circulation | |
Rimpiläinen et al. | Lamotrigine plus leukocyte filtration as a neuroprotective strategy in experimental hypothermic circulatory arrest | |
US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
JP4989071B2 (ja) | 赤ブドウ葉抽出物を含むフィルムコート錠 | |
Sarao et al. | Regression of diabetic macular edema after subcutaneous exenatide | |
Fadlan et al. | 12 GARCINIA MANGOSTANA LINN EXTRACT REDUCES SYSTOLIC BLOOD PRESSURE AND INFLAMATION PROCESS IN PATIENT'S WITH HYPERTENSION: COMPARASION WITH STANDAR BLOOD PRESSURE MEDICATION | |
Setyowati et al. | 13 CONTRIBUTORY OF PRECIPITATING FACTORS, COMORBIDITIES AND OUTCOMES IN PATIENT HOSPITALIZED WITH HEART FAILURE AND HYPERTENSION | |
Alsagaf et al. | 11 PLAUSIBLE INTERACTION BETWEEN HYPERTENSION AND NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS IN CHRONIC KIDNEY DISEASE: A PILOT STUDY | |
Almuhambetova et al. | THE MANEGEMENT OF HYPERTENSIVE CRISIS COMPLICATED BY THE PULMONARY EDEMA | |
CN116077481A (zh) | 消退素e1在制备缓解和/或治疗高血压病及其并发症药物中的应用 | |
CN113812377B (zh) | 一种烧伤合并慢性肾病实验模型的建立方法 | |
Torunova et al. | The influence of spironolactone addition to a standard antihypertensive therapy on the daily blood pressure profile in patients with hypertension | |
Tiara et al. | 5. Nocturnal Dipping Pattern in Hypertensive Patients as a Risk Factor for Cerebral Small Vessel Disease (CSVD): A Systematic Review and Meta-Analysis | |
CN117298091A (zh) | Sbfi-26在制备用于预防肝纤维化药物中的用途 | |
Lee et al. | EFFICACY AND SAFETY OF NEBIVOLOL IN THE MANAGEMENT OF HYPERTENSION IN THE ELDERLY: RESULT FROM BENEFIT-KOREA STUDY | |
CN112843070A (zh) | 鲁斯可皂苷元在制备脑出血防治药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |